MedTrace Logo

Clarithromycin in Multiple Myeloma Induction Therapy

NCT02573935 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-09-20

No results posted yet for this study

Summary

This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.

Conditions

Interventions

DRUG

Clarithromycin

p.o. clarithromycin 500 mg twice daily for 63 days

DRUG

Placebo

Placebo tablet twice daily for 63 days

DRUG

VCD induction therapy

Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)

Sponsors & Collaborators

  • Danish Myeloma Study Group

    collaborator OTHER

  • Henrik Gregersen

    lead OTHER

Principal Investigators

  • Henrik Gregersen, MD · Aalborg University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02573935 on ClinicalTrials.gov